Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group. Mattoo V, et al. Among authors: tan m. Clin Ther. 2005 May;27(5):554-67. doi: 10.1016/j.clinthera.2005.05.005. Clin Ther. 2005. PMID: 15978304 Clinical Trial.
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH. Pavo I, et al. Among authors: tan mh. J Clin Endocrinol Metab. 2003 Apr;88(4):1637-45. doi: 10.1210/jc.2002-021786. J Clin Endocrinol Metab. 2003. PMID: 12679450 Clinical Trial.
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH. Herz M, et al. Among authors: tan mh. Clin Ther. 2003 Apr;25(4):1074-95. doi: 10.1016/s0149-2918(03)80068-1. Clin Ther. 2003. PMID: 12809958 Clinical Trial.
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M, Johns D, González Gálvez G, Antúnez O, Fabián G, Flores-Lozano F, Zúñiga Guajardo S, Garza E, Morales H, Konkoy C, Herz M; GLAD Study Group. Tan M, et al. Clin Ther. 2004 May;26(5):680-93. doi: 10.1016/s0149-2918(04)90068-9. Clin Ther. 2004. PMID: 15220012 Clinical Trial.
Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ, Tan MH. Ceriello A, et al. Among authors: tan mh. Diabetes Care. 2005 Feb;28(2):266-72. doi: 10.2337/diacare.28.2.266. Diabetes Care. 2005. PMID: 15677777 Clinical Trial.
7,205 results